These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28800944)

  • 41. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
    Garcia-Soto AE; Schreiber T; Strbo N; Ganjei-Azar P; Miao F; Koru-Sengul T; Simpkins F; Nieves-Neira W; Lucci J; Podack ER
    Gynecol Oncol; 2017 Jun; 145(3):413-419. PubMed ID: 28392126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.
    Chatterjee M; Mohapatra S; Ionan A; Bawa G; Ali-Fehmi R; Wang X; Nowak J; Ye B; Nahhas FA; Lu K; Witkin SS; Fishman D; Munkarah A; Morris R; Levin NK; Shirley NN; Tromp G; Abrams J; Draghici S; Tainsky MA
    Cancer Res; 2006 Jan; 66(2):1181-90. PubMed ID: 16424057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HE4 in the differential diagnosis of ovarian masses.
    Granato T; Porpora MG; Longo F; Angeloni A; Manganaro L; Anastasi E
    Clin Chim Acta; 2015 Jun; 446():147-55. PubMed ID: 25892674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.
    Jia LT; Zhang YC; Li J; Tian Y; Li JF
    Clin Transl Oncol; 2016 Mar; 18(3):233-9. PubMed ID: 26220095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
    Dai L; Tsay JC; Li J; Yie TA; Munger JS; Pass H; Rom WN; Zhang Y; Tan EM; Zhang JY
    Lung Cancer; 2016 Sep; 99():172-9. PubMed ID: 27565936
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.
    Będkowska GE; Gacuta E; Zajkowska M; Głażewska EK; Osada J; Szmitkowski M; Chrostek L; Dąbrowska M; Ławicki S
    J Ovarian Res; 2017 Jun; 10(1):39. PubMed ID: 28662671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.
    Capriglione S; Luvero D; Plotti F; Terranova C; Montera R; Scaletta G; Schirò T; Rossini G; Benedetti Panici P; Angioli R
    Med Oncol; 2017 Aug; 34(9):164. PubMed ID: 28825178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.
    Ravi P; Freeman D; Thomas J; Ravi A; Mantia C; McGregor BA; Berchuck JE; Epstein I; Budde P; Ahangarian Abhari B; Rupieper E; Gajewski J; Schubert AS; Kilian AL; Bräutigam M; Zucht HD; Sonpavde G
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309723
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer.
    Chen H; Werner S; Tao S; Zörnig I; Brenner H
    Cancer Lett; 2014 May; 346(2):178-87. PubMed ID: 24462820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
    Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
    Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of autoantibodies to a panel of tumor-associated antigens for the diagnosis values of gastric cardia adenocarcinoma.
    Zhou SL; Ku JW; Fan ZM; Yue WB; Du F; Zhou YF; Liu YL; Li Y; Tang S; Hu YL; Hu XP; Hou ZC; Liu J; Liu Y; Feng XS; Wang LD
    Dis Esophagus; 2015; 28(4):371-9. PubMed ID: 24612004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
    Xi QP; Pu DH; Lu WN
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploring the immunoproteome for ovarian cancer biomarker discovery.
    Martin K; Ricciardelli C; Hoffmann P; Oehler MK
    Int J Mol Sci; 2011 Jan; 12(1):410-28. PubMed ID: 21339995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.